<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546984</url>
  </required_header>
  <id_info>
    <org_study_id>HEC96719-P-02/CRC-C2028</org_study_id>
    <nct_id>NCT04546984</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics，and Randomized, Open-label，Crossover, Food Effect Study of HEC96719 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719&#xD;
      in Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Actual">December 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of HEC96719 by Assessment of the Number of Adverse Events</measure>
    <time_frame>up to 17 days</time_frame>
    <description>To investigate the safety and tolerability of HEC96719 by assessment of AEs (non-serious and serious) following administration of oral solution in MAD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Maximum Plasma Concentration(Cmax)of HEC96719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Area Under the Curve(AUC) of HEC96719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Maximum Peak Time(Tmax) of HEC96719</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Maximum Peak Time(Tmax) of HEC96719</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Single dose of HEC96719 （Part 1，Fed/Fasting）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC96719 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC96719 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 3）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC96719 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 4）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC96719 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 5）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC96719 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC96719</intervention_name>
    <description>Part 2：Mulltiple doses up to 10 days</description>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 1）</arm_group_label>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 2）</arm_group_label>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 3）</arm_group_label>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 4）</arm_group_label>
    <arm_group_label>Mulltiple doses HEC96719（ Part 2, Cohort 5）</arm_group_label>
    <arm_group_label>Single dose of HEC96719 （Part 1，Fed/Fasting）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study, able to understand and sign the informed consent,&#xD;
             and able to complete the the study in accordance with the requirements of the study.&#xD;
&#xD;
          -  Female subjects who are not pregnant or lactating and male subjects whose female&#xD;
             partners are fertile shall voluntarily take effective contraceptive measures from the&#xD;
             date of signing the informed consent form to 3 months after the medication.&#xD;
&#xD;
          -  When signing the informed consent, 18 years old ≤the age≤45 years old(including the&#xD;
             critical value), gender is not limited.&#xD;
&#xD;
          -  Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the&#xD;
             range of 18-28 kg/m2 (including the critical value).&#xD;
&#xD;
          -  No clinical significance of vital signs, physical examination, laboratory examination,&#xD;
             electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior)&#xD;
             results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis.&#xD;
&#xD;
          -  Those who are known to have allergy history or allergy constitution to the test&#xD;
             preparation and any of its components or related preparations.&#xD;
&#xD;
          -  Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          -  Positive results from urine drug screen test.&#xD;
&#xD;
          -  Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
          -  Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
          -  Subjects considered by the investigator to have other factors unsuitable for&#xD;
             participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Shanghai xuhui district central hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

